ALZN Insider Trading

Insider Ownership Percentage: 9.77%
Insider Buying (Last 12 Months): $4,456,448.50
Insider Selling (Last 12 Months): $24,200.00

Alzamend Neuro Insider Trading History Chart

This chart shows the insider buying and selling history at Alzamend Neuro by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alzamend Neuro Share Price & Price History

Current Price: $0.44
Price Change: Price Increase of +0.01 (2.33%)
As of 03/24/2023 01:00 AM ET

This chart shows the closing price history over time for ALZN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Alzamend Neuro Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/22/2023Lynne Fahey McgrathDirectorBuy10,000$0.43$4,300.0010,000View SEC Filing Icon  
3/16/2023Milton C. Ault IIIMajor ShareholderBuy4,000$0.50$2,000.0011,055,001View SEC Filing Icon  
2/15/2023Milton C. Ault IIIMajor ShareholderBuy1,000$0.60$600.0011,051,001View SEC Filing Icon  
12/27/2022Milton C. Ault IIIMajor ShareholderBuy900$0.59$531.0011,046,901View SEC Filing Icon  
11/18/2022Milton C. Ault IIIMajor ShareholderBuy1,000$1.29$1,290.0011,038,001View SEC Filing Icon  
10/31/2022Milton C. Ault IIIMajor ShareholderBuy6,000$1.19$7,140.0010,102,667View SEC Filing Icon  
10/12/2022Milton C. Ault IIIMajor ShareholderBuy2,000$1.23$2,460.0010,096,667View SEC Filing Icon  
10/6/2022Milton C. Ault IIIMajor ShareholderBuy1,000$1.43$1,430.0010,094,667View SEC Filing Icon  
9/29/2022Milton C. Ault IIIMajor ShareholderBuy3,500$1.19$4,165.0010,093,667View SEC Filing Icon  
9/19/2022Stephan JackmanCEOBuy8,500$1.23$10,455.008,500View SEC Filing Icon  
9/14/2022David J KatzoffCFOBuy10,000$1.11$11,100.0028,000View SEC Filing Icon  
8/25/2022Milton C. Ault IIIMajor ShareholderBuy4,900$0.96$4,704.0010,007,567View SEC Filing Icon  
8/22/2022Milton C. Ault IIIMajor ShareholderBuy36,000$0.97$34,920.0010,002,667View SEC Filing Icon  
8/15/2022Milton C. Ault IIIMajor ShareholderBuy14,000$1.06$14,840.009,951,667View SEC Filing Icon  
8/3/2022Milton C. Ault IIIMajor ShareholderBuy2,000$0.95$1,900.009,936,667View SEC Filing Icon  
7/27/2022Milton C. Ault IIIMajor ShareholderBuy5,700$0.87$4,959.009,934,667View SEC Filing Icon  
7/22/2022Milton C. Ault IIIMajor ShareholderBuy2,300$0.91$2,093.009,928,967View SEC Filing Icon  
7/18/2022Milton C. Ault IIIMajor ShareholderBuy10,000$0.98$9,800.009,926,667View SEC Filing Icon  
6/29/2022Milton C. Ault IIIMajor ShareholderBuy10,000$0.88$8,800.009,916,667View SEC Filing Icon  
6/17/2022Milton C. Ault IIIMajor ShareholderBuy10,000$0.88$8,800.009,906,667View SEC Filing Icon  
6/14/2022Milton C. Ault IIIMajor ShareholderBuy10,000$0.85$8,500.009,886,667View SEC Filing Icon  
6/7/2022Milton C. Ault IIIMajor ShareholderBuy2,000$0.94$1,880.009,868,667View SEC Filing Icon  
6/2/2022Milton C. Ault IIIMajor ShareholderBuy8,000$0.96$7,680.009,866,667View SEC Filing Icon  
5/26/2022Milton C. Ault IIIMajor ShareholderBuy10,000$0.91$9,100.009,846,667View SEC Filing Icon  
5/24/2022Milton C. Ault IIIMajor ShareholderBuy16,100$0.89$14,329.009,836,667View SEC Filing Icon  
5/17/2022Milton C. Ault IIIMajor ShareholderBuy23,900$0.98$23,422.009,815,567View SEC Filing Icon  
5/12/2022Milton C. Ault IIIMajor ShareholderBuy25,000$0.85$21,250.009,791,667View SEC Filing Icon  
5/5/2022Milton C. Ault IIIMajor ShareholderBuy100,000$1.07$107,000.00325,000View SEC Filing Icon  
4/26/2022Milton C. Ault IIIMajor ShareholderBuy2,666,667$1.50$4,000,000.509,666,667View SEC Filing Icon  
4/22/2022Milton C. Ault IIIMajor ShareholderBuy75,000$0.94$70,500.00225,000View SEC Filing Icon  
4/11/2022Milton C. Ault IIIMajor ShareholderBuy50,000$1.13$56,500.00150,000View SEC Filing Icon  
3/31/2022Mark GustafsonDirectorSell20,000$1.21$24,200.0060,000View SEC Filing Icon  
3/18/2022Milton C. Ault IIIMajor ShareholderBuy100,000$1.10$110,000.00View SEC Filing Icon  
2/24/2022Milton C. Ault IIIMajor ShareholderBuy22,500$1.15$25,875.00View SEC Filing Icon  
1/27/2022Milton C. Ault IIIMajor ShareholderBuy2,500$1.40$3,500.00View SEC Filing Icon  
1/24/2022Milton C. Ault IIIMajor ShareholderBuy5,000$1.29$6,450.00View SEC Filing Icon  
1/18/2022Milton C. Ault IIIMajor ShareholderBuy7,000$1.66$11,620.00View SEC Filing Icon  
1/14/2022Milton C. Ault IIIMajor ShareholderBuy3,000$1.79$5,370.00View SEC Filing Icon  
1/7/2022Milton C. Ault IIIMajor ShareholderBuy3,000$1.93$5,790.00View SEC Filing Icon  
1/5/2022Milton C. Ault IIIMajor ShareholderBuy2,000$1.98$3,960.00View SEC Filing Icon  
12/23/2021Milton C. Ault IIIMajor ShareholderBuy1,612$2.10$3,385.20View SEC Filing Icon  
12/20/2021Milton C. Ault IIIMajor ShareholderBuy25,000$2.11$52,750.00View SEC Filing Icon  
12/17/2021Milton C. Ault IIIMajor ShareholderBuy13,000$2.48$32,240.00View SEC Filing Icon  
12/14/2021Mark GustafsonDirectorSell20,000$2.85$57,000.00View SEC Filing Icon  
11/30/2021Milton C. Ault IIIMajor ShareholderBuy5,319$2.27$12,074.13View SEC Filing Icon  
11/22/2021Milton C. Ault IIIMajor ShareholderBuy15,000$1.90$28,500.00View SEC Filing Icon  
11/8/2021Milton C. Ault IIIMajor ShareholderBuy145,000$2.57$372,650.00View SEC Filing Icon  
9/14/2021Milton C. Ault IIIMajor ShareholderBuy5,000$2.70$13,500.00150,000View SEC Filing Icon  
8/27/2021Milton C. Ault IIIMajor ShareholderBuy6,000$2.90$17,400.00View SEC Filing Icon  
8/17/2021Milton C. Ault IIIMajor ShareholderBuy4,000$3.29$13,160.00View SEC Filing Icon  
8/12/2021Milton C. Ault IIIMajor ShareholderBuy3,400$3.87$13,158.00View SEC Filing Icon  
8/9/2021Milton C. Ault IIIMajor ShareholderBuy500$4.05$2,025.00View SEC Filing Icon  
8/6/2021Milton C. Ault IIIMajor ShareholderBuy4,000$4.07$16,280.00View SEC Filing Icon  
8/4/2021Milton C. Ault IIIMajor ShareholderBuy500$4.30$2,150.00View SEC Filing Icon  
8/2/2021Milton C. Ault IIIMajor ShareholderBuy1,500$4.56$6,840.00View SEC Filing Icon  
7/30/2021Milton C. Ault IIIMajor ShareholderBuy1,338,333$1.51$2,020,882.83View SEC Filing Icon  
7/26/2021Milton C. Ault IIIMajor ShareholderBuy3,500$4.94$17,290.00View SEC Filing Icon  
7/23/2021Milton C. Ault IIIMajor ShareholderBuy5,000$5.76$28,800.00View SEC Filing Icon  
7/19/2021Milton C. Ault IIIMajor ShareholderBuy4,000$5.41$21,640.00View SEC Filing Icon  
7/16/2021Milton C. Ault IIIMajor ShareholderBuy600$6.23$3,738.00View SEC Filing Icon  
7/14/2021Milton C. Ault IIIMajor ShareholderBuy5,000$6.74$33,700.00View SEC Filing Icon  
7/12/2021Milton C. Ault IIIMajor ShareholderBuy8,100$6.15$49,815.00View SEC Filing Icon  
7/8/2021Milton C. Ault IIIMajor ShareholderBuy2,000$6.08$12,160.00View SEC Filing Icon  
7/6/2021Milton C. Ault IIIMajor ShareholderBuy7,000$7.07$49,490.00View SEC Filing Icon  
6/28/2021Milton C. Ault IIIMajor ShareholderBuy9,000$9.61$86,490.00View SEC Filing Icon  
6/25/2021Milton C. Ault IIIMajor ShareholderBuy14,000$8.79$123,060.00View SEC Filing Icon  
6/22/2021Milton C. Ault IIIMajor ShareholderBuy74,000$9.29$687,460.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Alzamend Neuro (NASDAQ:ALZN)

0.95% of Alzamend Neuro stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ALZN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Alzamend Neuro Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/15/2023Virtu Financial LLC62,660$35K0.0%N/A0.065%Search for SEC Filing on Google Icon
2/13/2023Charles Schwab Investment Management Inc.53,080$30K0.0%N/A0.055%Search for SEC Filing on Google Icon
2/13/2023Renaissance Technologies LLC49,800$28K0.0%N/A0.052%Search for SEC Filing on Google Icon
2/13/2023Geode Capital Management LLC563,660$0.32M0.0%+7.2%0.585%Search for SEC Filing on Google Icon
2/10/2023HRT Financial LP57,080$32K0.0%N/A0.059%Search for SEC Filing on Google Icon
11/15/2022Vanguard Group Inc.4,095,775$4.87M0.0%+6,642.3%4.290%Search for SEC Filing on Google Icon
11/15/2022BlackRock Inc.596,129$0.71M0.0%N/A0.624%Search for SEC Filing on Google Icon
8/15/2022Millennium Management LLC49,223$43K0.0%-65.4%0.052%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC65,131$56K0.0%N/A0.068%Search for SEC Filing on Google Icon
6/7/2022Bank of America Corp DE28,197$35K0.0%N/A0.031%Search for SEC Filing on Google Icon
5/11/2022RFG Advisory LLC250,000$0.31M0.0%N/A0.277%Search for SEC Filing on Google Icon
5/9/2022Qube Research & Technologies Ltd78,465$97K0.0%N/A0.087%Search for SEC Filing on Google Icon
4/22/2022Truist Financial Corp2,314,907$2.85M0.0%N/A2.569%Search for SEC Filing on Google Icon
1/31/2022Commonwealth Equity Services LLC116,666$0.22M0.0%N/A0.131%Search for SEC Filing on Google Icon
11/16/2021Schonfeld Strategic Advisors LLC31,600$97K0.0%N/A0.036%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Investments LP172,913$0.53M0.0%N/A0.199%Search for SEC Filing on Google Icon
11/16/2021Warberg Asset Management LLC14,000$43K0.0%N/A0.016%Search for SEC Filing on Google Icon
11/15/2021Sassicaia Capital Advisers LLC93,762$0.29M0.8%N/A0.108%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC15,402$0.14M0.0%N/A0.018%Search for SEC Filing on Google Icon
8/16/2021Cubist Systematic Strategies LLC23,672$0.21M0.0%N/A0.028%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC44,600$0.39M0.0%N/A0.052%Search for SEC Filing on Google Icon
8/11/2021Susquehanna International Group LLP57,030$0.50M0.0%N/A0.067%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Alzamend Neuro logo
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Read More on Alzamend Neuro

Today's Range

Now: $0.44
Low: $0.41
High: $0.44

50 Day Range

MA: $0.57
Low: $0.37
High: $0.71

52 Week Range

Now: $0.44
Low: $0.31
High: $1.50


102,251 shs

Average Volume

205,717 shs

Market Capitalization

$42.43 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Alzamend Neuro?

Alzamend Neuro's top insider shareholders include:
  1. Milton C Ault III (Major Shareholder)
  2. Mark Gustafson (Director)
  3. David J Katzoff (CFO)
  4. Lynne Fahey Mcgrath (Director)
  5. Stephan Jackman (CEO)
  6. L Mary Smith (Insider)
Learn More about top insider investors at Alzamend Neuro.

Who are the major institutional investors of Alzamend Neuro?

Alzamend Neuro's top institutional shareholders include:
  1. Geode Capital Management LLC — 0.58%
  2. Virtu Financial LLC — 0.06%
  3. HRT Financial LP — 0.06%
  4. Charles Schwab Investment Management Inc. — 0.06%
  5. Renaissance Technologies LLC — 0.05%
  6. Susquehanna International Group LLP — 0.00%
Learn More about top institutional investors of Alzamend Neuro stock.

Which institutional investors are selling Alzamend Neuro stock?

Within the last quarter, ALZN stock was sold by these institutional investors:
  1. Group One Trading L.P.

Which institutional investors are buying Alzamend Neuro stock?

Within the last quarter, ALZN stock was acquired by institutional investors including:
  1. Virtu Financial LLC
  2. HRT Financial LP
  3. Charles Schwab Investment Management Inc.
  4. Renaissance Technologies LLC
  5. Geode Capital Management LLC
  6. Susquehanna International Group LLP
Within the previous year, these company insiders have bought Alzamend Neuro stock:
  1. Milton C Ault III (Major Shareholder)
  2. Mark Gustafson (Director)
  3. David J Katzoff (CFO)
  4. Lynne Fahey Mcgrath (Director)
Learn More investors buying Alzamend Neuro stock.